108 related articles for article (PubMed ID: 1506980)
1. An enzyme immunoassay for determining plasma concentrations of didemnin B.
Raybould TJ; Grothaus PG; Simpson SB; Bignami GS; Lazo CB; Newman RA
J Clin Lab Anal; 1992; 6(3):136-42. PubMed ID: 1506980
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.
Benvenuto JA; Newman RA; Bignami GS; Raybould TJ; Raber MN; Esparza L; Walters RS
Invest New Drugs; 1992 Jul; 10(2):113-7. PubMed ID: 1500265
[TBL] [Abstract][Full Text] [Related]
3. An enzyme immunoassay for the determination of taxol and taxanes in Taxus sp. tissues and human plasma.
Grothaus PG; Raybould TJ; Bignami GS; Lazo CB; Byrnes JB
J Immunol Methods; 1993 Jan; 158(1):5-15. PubMed ID: 8094087
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and cellular effects of didemnins A and B.
Crampton SL; Adams EG; Kuentzel SL; Li LH; Badiner G; Bhuyan BK
Cancer Res; 1984 May; 44(5):1796-801. PubMed ID: 6713383
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of didemnin B.
Stewart JA; Low JB; Roberts JD; Blow A
Cancer; 1991 Dec; 68(12):2550-4. PubMed ID: 1933801
[TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody-based immunoassay for detecting tetrodotoxin in biological samples.
Raybould TJ; Bignami GS; Inouye LK; Simpson SB; Byrnes JB; Grothaus PG; Vann DC
J Clin Lab Anal; 1992; 6(2):65-72. PubMed ID: 1403332
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
Dorr FA; Kuhn JG; Phillips J; von Hoff DD
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study.
Weiss RB; Peterson BL; Allen SL; Browning SM; Duggan DB; Schiffer CA
Invest New Drugs; 1994; 12(1):41-3. PubMed ID: 7960604
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
Hochster H; Oratz R; Ettinger DS; Borden E
Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-based enzyme-linked immunoassays for the measurement of palytoxin in biological samples.
Bignami GS; Raybould TJ; Sachinvala ND; Grothaus PG; Simpson SB; Lazo CB; Byrnes JB; Moore RE; Vann DC
Toxicon; 1992 Jul; 30(7):687-700. PubMed ID: 1354900
[TBL] [Abstract][Full Text] [Related]
11. A Semisynthesis Platform for the Efficient Production and Exploration of Didemnin-Based Drugs.
Zhang H; Li X; Hui Z; Huang S; Cai M; Shi W; Lin Y; Shen J; Sui M; Lai Q; Shao Z; Dou J; Luo X; Ge Y; Tang X
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202318784. PubMed ID: 38291557
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).
Mittelman A; Chun HG; Puccio C; Coombe N; Lansen T; Ahmed T
Invest New Drugs; 1999; 17(2):179-82. PubMed ID: 10638489
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Giroux DJ; Jaeckle KA; Panella TJ; Dakhil SR; Schold SC
Invest New Drugs; 1998-1999; 16(4):331-2. PubMed ID: 10426666
[TBL] [Abstract][Full Text] [Related]
14. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
[TBL] [Abstract][Full Text] [Related]
15. Multiwavelength videomicrofluorometric study of cytotoxic effects of a marine peptide, didemnin B, on normal and MDR resistant CCRF-CEM cell lines.
Rocchi E; Vigo J; Viallet P; Bonnard I; Salmon JM
Anticancer Res; 2000; 20(2A):987-96. PubMed ID: 10810386
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Jacobs AJ
Am J Clin Oncol; 1993 Feb; 16(1):47-9. PubMed ID: 8424404
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Shin DM; Holoye PY; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber MN; Hong WK
Invest New Drugs; 1994; 12(3):243-9. PubMed ID: 7896544
[TBL] [Abstract][Full Text] [Related]
18. New highly sensitive enzyme immunoassay for the determination of pravastatin in human plasma.
Darwish IA; Al-Obaid AR; Al-Malaq HA
Talanta; 2009 Oct; 79(5):1478-83. PubMed ID: 19635387
[TBL] [Abstract][Full Text] [Related]
19. The generation of antibody in mice to tuftsin: a naturally occurring phagocytosis stimulating tetrapeptide.
Naim JO; van Oss CJ
Immunol Invest; 1991 Jul; 20(4):351-64. PubMed ID: 1937582
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.
Williamson SK; Wolf MK; Eisenberger MA; O'Rourke M; Brannon W; Crawford ED
Invest New Drugs; 1995; 13(2):167-70. PubMed ID: 8617581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
